Search
- Page Path
-
HOME
> Search
Review article
- Clinical readiness of artificial intelligence for treat-to-target management in inflammatory bowel disease: from scores to decisions
-
You Jin Choi, Seom Gim Kong, So Yoon Choi
-
Kosin Med J. 2026;41(3):185-202. Published online September 30, 2026
-
DOI: https://doi.org/10.7180/kmj.26.197
-
-
Abstract
PDF
PubReader
ePub
- Artificial intelligence (AI) is increasingly used in inflammatory bowel disease (IBD), particularly for endoscopy, histology, transmural imaging, and prediction of treatment response. However, strong diagnostic or predictive performance does not necessarily confer clinical utility. This narrative review traces the development of AI in IBD from objective disease assessment and outcome prediction to therapeutic decision support within a treat-to-target framework. Endoscopic AI has the most mature evidence base, while applications in histology and transmural imaging are at earlier stages of clinical translation. Models of treatment response can stratify patients by the likelihood of response, remission, relapse, or treatment sustainability; most, however, remain prognostic rather than prescriptive. We therefore propose the clinical readiness of AI in IBD framework, comprising analytical validity, clinical validity, generalizability, workflow utility, decision utility, and clinical impact. The strongest evidence concerns disease measurement and prediction; evidence that AI-informed or AI-guided strategies improve treatment decisions and patient outcomes remains limited. Future research should prioritize external validation, prospective evaluation in clinical workflows, comparative trials of prespecified AI-informed or AI-guided treatment strategies, and patient-important outcomes.
Case report
- Complete response in borderline resectable pancreatic cancer after modified FOLFIRINOX chemotherapy followed by surgical resection: a case report
-
Seong Hyun Koh, Jung Wook Lee
-
Kosin Med J. 2025;40(2):136-141. Published online June 18, 2025
-
DOI: https://doi.org/10.7180/kmj.24.158
-
-
Abstract
PDF
PubReader
ePub
- Borderline resectable pancreatic cancer (BRPC) constitutes a challenging subset of cases that fall between clearly resectable and unresectable disease. Pancreatic cancer has a poor prognosis, with a 5-year survival rate of 4.2%. In patients who underwent surgical resection, the 5-year survival rate rose from 1.5% to 17.4%, whereas in those who did not undergo resection, it remained unchanged. Here, we present the case of a patient with BRPC who had no residual tumor during surgery after receiving neoadjuvant FOLFIRINOX chemotherapy. A 57-year-old male patient was hospitalized for abdominal pain and was referred to our hospital for recurrent pancreatitis due to persistent alcohol consumption. Tumor marker testing showed a carbohydrate antigen 19-9 level <2.00 U/mL and a carcinoembryonic antigen level of 4.32 ng/mL. Computed tomography and magnetic resonance cholangiopancreatography revealed signs suggestive of pancreatic cancer, including diffuse gallbladder wall thickening and pancreatic duct dilatation. Endoscopic ultrasound-guided fine needle aspiration biopsy was performed to obtain a tissue sample, and pathological examination confirmed pancreatic ductal adenocarcinoma. Positron emission tomography-computed tomography found no abnormal F-18 fluorodeoxyglucose uptake that would suggest metastasis. Pylorus-preserving pancreaticoduodenectomy was performed, and no visible tumor cells were detected in the resected pancreas after chemotherapy. The patient was followed up for >2 months after surgery without recurrence. The absence of a residual tumor during surgery after upfront chemotherapy in patients with pancreatic cancer is extremely rare and is reported here along with a review of the literature.
TOP